Mead Simon, Poulter Mark, Uphill James, Beck John, Whitfield Jerome, Webb Thomas E F, Campbell Tracy, Adamson Gary, Deriziotis Pelagia, Tabrizi Sarah J, Hummerich Holger, Verzilli Claudio, Alpers Michael P, Whittaker John C, Collinge John
Medical Research Council Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London, UK.
Lancet Neurol. 2009 Jan;8(1):57-66. doi: 10.1016/S1474-4422(08)70265-5.
Human and animal prion diseases are under genetic control, but apart from PRNP (the gene that encodes the prion protein), we understand little about human susceptibility to bovine spongiform encephalopathy (BSE) prions, the causal agent of variant Creutzfeldt-Jakob disease (vCJD).
We did a genome-wide association study of the risk of vCJD and tested for replication of our findings in samples from many categories of human prion disease (929 samples) and control samples from the UK and Papua New Guinea (4254 samples), including controls in the UK who were genotyped by the Wellcome Trust Case Control Consortium. We also did follow-up analyses of the genetic control of the clinical phenotype of prion disease and analysed candidate gene expression in a mouse cellular model of prion infection.
The PRNP locus was strongly associated with risk across several markers and all categories of prion disease (best single SNP [single nucleotide polymorphism] association in vCJD p=2.5 x 10(-17); best haplotypic association in vCJD p=1 x 10(-24)). Although the main contribution to disease risk was conferred by PRNP polymorphic codon 129, another nearby SNP conferred increased risk of vCJD. In addition to PRNP, one technically validated SNP association upstream of RARB (the gene that encodes retinoic acid receptor beta) had nominal genome-wide significance (p=1.9 x 10(-7)). A similar association was found in a small sample of patients with iatrogenic CJD (p=0.030) but not in patients with sporadic CJD (sCJD) or kuru. In cultured cells, retinoic acid regulates the expression of the prion protein. We found an association with acquired prion disease, including vCJD (p=5.6 x 10(-5)), kuru incubation time (p=0.017), and resistance to kuru (p=2.5 x 10(-4)), in a region upstream of STMN2 (the gene that encodes SCG10). The risk genotype was not associated with sCJD but conferred an earlier age of onset. Furthermore, expression of Stmn2 was reduced 30-fold post-infection in a mouse cellular model of prion disease.
The polymorphic codon 129 of PRNP was the main genetic risk factor for vCJD; however, additional candidate loci have been identified, which justifies functional analyses of these biological pathways in prion disease.
人类和动物的朊病毒疾病受遗传控制,但除了PRNP(编码朊病毒蛋白的基因)外,我们对人类对牛海绵状脑病(BSE)朊病毒(变异型克雅氏病(vCJD)的病原体)的易感性了解甚少。
我们对vCJD风险进行了全基因组关联研究,并在来自多种人类朊病毒疾病的样本(929个样本)以及来自英国和巴布亚新几内亚的对照样本(4254个样本)中对研究结果进行了验证,其中包括由威康信托病例对照研究联盟进行基因分型的英国对照。我们还对朊病毒疾病临床表型的遗传控制进行了后续分析,并在朊病毒感染的小鼠细胞模型中分析了候选基因的表达。
PRNP基因座与多个标记以及所有类型的朊病毒疾病风险密切相关(vCJD中最佳单核苷酸多态性(SNP)关联p = 2.5×10⁻¹⁷;vCJD中最佳单倍型关联p = 1×10⁻²⁴)。尽管疾病风险的主要贡献由PRNP多态密码子129决定,但另一个附近的SNP增加了vCJD的风险。除PRNP外,RARB(编码视黄酸受体β的基因)上游一个经过技术验证的SNP关联具有全基因组名义显著性(p = 1.9×10⁻⁷)。在一小部分医源性克雅氏病患者中发现了类似的关联(p = 0.030),但在散发性克雅氏病(sCJD)或库鲁病患者中未发现。在培养细胞中,视黄酸调节朊病毒蛋白的表达。我们在STMN2(编码SCG10的基因)上游区域发现了与获得性朊病毒疾病的关联,包括vCJD(p = 5.6×10⁻⁵)、库鲁病潜伏期(p = 0.017)和对库鲁病的抵抗力(p = 2.5×10⁻⁴)。风险基因型与sCJD无关,但与发病年龄较早有关。此外,在朊病毒疾病的小鼠细胞模型中,感染后Stmn2的表达降低了30倍。
PRNP的多态密码子129是vCJD的主要遗传风险因素;然而,已鉴定出其他候选基因座,这证明对朊病毒疾病中这些生物学途径进行功能分析是合理的。